|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Recombinant Human IL-33 protein (Catalog#10368-HNAE)|
|10 μl/Test, 0.1 mg/ml|
|Aqueous solution containing 0.5% BSA and 0.09% sodium azide|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL-33 (rh IL-33; Catalog#10368-HNAE; NP_254274.1; Ser 112-Thr 270) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.|
No cross-reactivity in ELISA with
Human cell lysate (293 cell line)
|This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze ! |
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Flow cytometric analysis of Human IL-33 on HUVEC cells. HUVEC cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), and stained with FITC Mouse anti-IL-33 (Bold line hisgram).
Interleukin 33 (IL-33), also known as DVS27 or NF-HEV (Nuclear Factor from High Endothelial enules), is a proinflammatory protein and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 protein is expressed highly and rather selectively by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. IL-33 protein has transcriptional regulatory properties, and the researches suggested that IL-33 is a dual-function protein that might act both as a cytokine and as an intracellular nuclear factor. As a type 2 cytokines, IL-33 protein also play a pivotal role in helminthic infection and allergic disorders.